published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COLCOVID, 2021 0.88 [0.70; 1.11] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] Horby, 2021 1.01 [0.93; 1.10] Lanzoni, 2021 0.14 [0.02; 0.96] RECOVERY (colchicine), 2021 1.01 [0.93; 1.10] Shi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] 0.99[0.94; 1.06]COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Horby, 2021, Lanzoni, 2021, RECOVERY (colchicine), 2021, Shi, 2020, Shu, 202083%24,541moderateserious deathsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COLCOVID, 2021 0.88 [0.70; 1.11] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] GRECCO-19, 2020 0.21 [0.02; 1.97] Horby, 2021 1.01 [0.93; 1.10] Lanzoni, 2021 0.11 [0.01; 0.93] RECOVERY (colchicine), 2021 1.01 [0.93; 1.10] Salehzadeh, 2020 1.00 [0.02; 51.41] Shi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] 0.99[0.94; 1.06]COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Horby, 2021, Lanzoni, 2021, RECOVERY (colchicine), 2021, Salehzadeh, 2020, Shi, 2020, Shu, 2020101%24,746moderatecritical deaths (time to event analysis only)detailed resultsCOLCOVID, 2021 0.88 [0.70; 1.11] Lanzoni, 2021 0.11 [0.01; 0.93] 0.42[0.06; 2.87]COLCOVID, 2021, Lanzoni, 2021272%1,303moderatenot evaluable clinical deteriorationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] GRECCO-19, 2020 0.11 [0.01; 1.08] Shu, 2020 0.27 [0.01; 5.58] 0.27[0.09; 0.83]COL-COVID (Pascual-Figal), 2021, GRECCO-19, 2020, Shu, 202030%249moderatenot evaluable clinical improvementdetailed resultsShu, 2020 10.27 [1.17; 90.18] 10.27[1.17; 90.18]Shu, 202010%41NAnot evaluable clinical improvement (14-day)detailed resultsShu, 2020 10.27 [1.17; 90.18] 10.27[1.17; 90.18]Shu, 202010%41NAnot evaluable clinical improvement (28-day)detailed resultsShu, 2020 3.68 [0.18; 75.54] 3.68[0.18; 75.54]Shu, 202010%41NAnot evaluable clinical improvement (7-day)detailed resultsShu, 2020 6.72 [1.50; 30.07] 6.72[1.50; 30.07]Shu, 202010%41NAnot evaluable death or ventilationdetailed resultsCOLCOVID, 2021 0.83 [0.67; 1.02] RECOVERY (colchicine), 2021 1.02 [0.96; 1.09] 0.94[0.78; 1.15]COLCOVID, 2021, RECOVERY (colchicine), 2021270%12,090moderatenot evaluable hospital dischargedetailed resultsRECOVERY (colchicine), 2021 0.98 [0.94; 1.03] 0.98[0.94; 1.03]RECOVERY (colchicine), 202110%11,340NAnot evaluable mechanical ventilationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06] GRECCO-19, 2020 0.17 [0.02; 1.48] RECOVERY (colchicine), 2021 1.04 [0.93; 1.16] Shu, 2020 0.59 [0.02; 14.04] 0.94[0.76; 1.15]COL-COVID (Pascual-Figal), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, RECOVERY (colchicine), 2021, Shu, 2020534%11,336moderateserious radiologic improvement (14-day)detailed resultsRashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28] 2.87[1.56; 5.28]Rashad (CLARI vs SoC), 202110%198NAnot evaluable ICU admissiondetailed resultsCOL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75] 0.92[0.54; 1.58]COL-COVID (Pascual-Figal), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 202120%330moderatenot evaluable recoverydetailed resultsLanzoni, 2021 3.46 [1.05; 11.35] 3.46[1.05; 11.35]Lanzoni, 202110%24NAnot evaluable serious adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] Lanzoni, 2021 0.10 [0.01; 0.69] Shi, 2020 1.08 [0.04; 32.96] 0.19[0.04; 0.84]COL-COVID (Pascual-Figal), 2021, Lanzoni, 2021, Shi, 202030%227moderatenot evaluable adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] Lanzoni, 2021 0.18 [0.02; 1.95] Shi, 2020 0.88 [0.38; 2.03] Shu, 2020 2.48 [0.05; 132.54] 1.07[0.53; 2.16]COL-COVID (Pascual-Figal), 2021, Lanzoni, 2021, Shi, 2020, Shu, 2020418%268moderatenot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-03-29 09:35 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290